(NASDAQ: HOWL) Werewolf Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Werewolf Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast HOWL's revenue for 2026 to be $2,286,449,950, with the lowest HOWL revenue forecast at $2,286,449,950, and the highest HOWL revenue forecast at $2,286,449,950. On average, 1 Wall Street analysts forecast HOWL's revenue for 2027 to be $425,279,691, with the lowest HOWL revenue forecast at $425,279,691, and the highest HOWL revenue forecast at $425,279,691.
In 2028, HOWL is forecast to generate $746,525,909 in revenue, with the lowest revenue forecast at $4,572,900 and the highest revenue forecast at $1,929,763,758.